Vanguard Group Inc Macrogenics Inc Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Macrogenics Inc stock. As of the latest transaction made, Vanguard Group Inc holds 4,357,540 shares of MGNX stock, worth $14.2 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,357,540
Previous 4,135,319
5.37%
Holding current value
$14.2 Million
Previous $17.6 Million
18.43%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding MGNX
# of Institutions
132Shares Held
55.4MCall Options Held
215KPut Options Held
238K-
Bellevue Group Ag Kuesnacht, V89.93MShares$32.4 Million0.55% of portfolio
-
Armistice Capital, LLC New York, NY6.26MShares$20.4 Million0.34% of portfolio
-
Black Rock Inc. New York, NY5.4MShares$17.6 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.54MShares$11.5 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.01MShares$9.81 Million0.53% of portfolio
About MACROGENICS INC
- Ticker MGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,458,800
- Market Cap $200M
- Description
- MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...